At Polymed we focus on novel therapies in the areas of oncology and auto-immune diseases. We aim at creating first-in-class and best-in-class medicines for treating patients using advanced technology platforms including artificial intelligence and structural biology. The approaches we use includes traditional protein inhibition and modern protein degradation. The aim is to deliver drugs for “undruggable” targets.